利特昔替尼(Ritlecitinib)不同版本的最新价格

Introduction: Ritlecitinib is an oral selective dual JAK3/TEC family kinase inhibitor that has demonstrated efficacy for up to 48 weeks and an acceptable safety profile in patients with alopecia areata over 12 years of age. Ritlecitinib has been approved in the United States, Japan, China and other countries for the treatment of severe alopecia areata in patients aged 12 years and above.

The latest prices of different versions of Ritlecitinib

The prices of different versions are also different.

1. Original research version: Ritexitinib developed by Pfizer in the United States is the original research version. It is currently on the market in China and has been included in medical insurance. The winning bid price of the drug is 2800$. The price after reimbursement will be cheaper. The specific drug price needs to be calculated according to the local reimbursement ratio.

2. Generic version: The currently known generic version of ritexitinib is produced by Lucius Pharmaceuticals in Laos. The specification of a box is 50mg*28 tablets. The current price is about 1200$-1600$ per box.

It may change due to factors such as region, pharmacy, medical insurance policy, drug version, etc. It is recommended to consult a doctor or pharmacist before purchasing to understand the actual local price. At the same time, choose formal channels to purchase to ensure product quality.

Ritlecitinib (Ritlecitinib) Treatment Effect

In ALLEGRO-2b/3, patients ≥12 years of age with alopecia areata and ≥50% scalp hair loss received Ritlecitinib 50 or 30 mg (± 4 weeks of 200 mg loading dose) or 10 mg or placebo once daily for 24 weeks. During the subsequent 24-week extension period, ritixitinib continued at its dose, with patients initially assigned to placebo switching to 200/50 or 50 mg daily, with a total of 105 adolescents randomized.

At Week 24, 17%-28% of those treated with ritixitinib 30 mg and higher had a Severity Alopecia Alopecia Tool (SALT) score of ≤20 (proportion of scalp hairless ≤20%), compared with 0% of the placebo group. At Week 48, 25%-50% of patients in the ritixitinib treatment group (30 mg and higher doses) had a SALT score ≤20.

At Week 24, 45%-61% of adolescents in the ritixitinib group (30 mg and higher doses) reported "moderate" or "much" improvement in alopecia areata (compared to 10%-22% in the placebo group), and 44%-80% at Week 48.

In adolescent patients with AA with ≥50% scalp alopecia, riteritinib treatment demonstrated clinically reported efficacy, patient-reported improvement, and acceptable safety at week 48.

Drug interactions of Ritlecitinib

1. CYP3A substrates where small changes in concentration may lead to serious adverse reactions: Ritlecitinib is a CYP3A inhibitor. Concomitant use of Ritlecitinib can increase the AUC and Cmax of CYP3A substrates, which may increase the risk of adverse reactions of these substrates. Additional monitoring and dosage adjustments need to be considered according to the approved CYP3A substrate product labeling, where small changes in concentration during use may lead to serious adverse reactions.

2. CYP1A2 substrates whose small changes in concentration may lead to serious adverse reactions: Ritexitinib is a CYP1A2 inhibitor. The combined use of Ritexitinib can increase the AUC and Cmax of CYP1A2 substrates, which may increase the risk of adverse reactions with these substrates. Additional monitoring and dose adjustments are required when both drugs are used together.